CC
CARM

Centiva Capital’s Carisma Therapeutics CARM Stock Holding History

Centiva Capital’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-54,500
Closed -$82.8K – 2174
2024
Q2 		$82.8K Buy
+54,500
New +$81.3K ﹤0.01% 1880
2021
Q4 		– Sell
-1,140
Closed -$17K – 1225
2021
Q3 		$17K Buy
+1,140
New +$54.7K ﹤0.01% 1188

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TOTUOP
Trustees of The University of Pennsylvania Philaldelphia, Pennsylvania $104M AUM
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Centiva Capital's CARM Position: Q3 2024 in Review

Centiva Capital sold out of Carisma Therapeutics (CARM) in Q3 2024, closing a stake of 54,500 shares — an estimated $82.8K sold.

Centiva Capital first reported a position in CARM in Q3 2021 and held it in 2 quarters. The position peaked at $82.8K in Q2 2024. 37 funds tracked by Wall St. Rank hold CARM as of Q3 2024.

  • Centiva Capital reported no remaining Carisma Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 54,500 Carisma Therapeutics shares in Q3 2024, an estimated $82.8K.
  • Centiva Capital first reported a position in Carisma Therapeutics in Q3 2021 and held it in 2 quarters.
  • Centiva Capital's Carisma Therapeutics position peaked at $82.8K in Q2 2024.
  • 37 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.